- Home
- Automated
- List of product information
- GLANATEC OPHTHALMIC SOLUTION 0.4% W/V [SIN15886P]
GLANATEC OPHTHALMIC SOLUTION 0.4% W/V [SIN15886P]
Active ingredients: GLANATEC OPHTHALMIC SOLUTION 0.4% W/V
Last updated 26 October 2025
On this page
Product Info
GLANATEC OPHTHALMIC SOLUTION 0.4% W/V
[SIN15886P]
Product information
Active Ingredient and Strength | RIPASUDIL HYDROCHLORIDE HYDRATE 0.4896 G EQUIV. TO RIPASUDIL - 0.4 G/100 ML |
Dosage Form | SOLUTION, STERILE |
Manufacturer and Country | TEIKA PHARMACEUTICAL CO., LTD. SHINJO FACTORY - JAPAN |
Registration Number | SIN15886P |
Licence Holder | DKSH SINGAPORE PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | PENDING |
4.1 Therapeutic indications
GLANATEC is indicated to decrease elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma as adjunctive therapy in patients who are insufficiently responsive to topical beta-blockers or prostaglandin analogues, or as monotherapy in patients who are intolerant or contraindicated to other intraocular pressure lowering medications.
4.2 Posology and method of administration
Posology
Use in adults, including the elderly
Instill one drop into the affected eye(s) twice daily.
Use in paediatric population
Safety in low birth weight infants, newborns, infants, and children has not been established.
Method of Administration
Route of administration: Instillation only.
When dispensing the drug: Instruct patients on the following:
In the instillation, the patient should tilt the head backwards, open the affected eye, instill the drug into the conjunctival sac, close the eyelid for 1 to 5 minutes while compressing the lacrimal part, and open the eye.
Be careful during the instillation to avoid direct contact of the tip of the container with the eye in order to prevent contamination of the drug.
Instill with an interval of at least 5 minutes when using the drug in combination with other ophthalmic solutions.
4.3 Contraindications
GLANATEC is contraindicated in patients with history of hypersensitivity to any of the components of GLANATEC (see Section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).